| Date | Title | Description |
| 03.10.2024 | The Week in AgriFoodTech: Fly farmer catches $58m, new deals for restaurant tech, TR4-resistant bananas | Restaurant tech was in the spotlight this week as food delivery app HungryPanda and software startup Dinii both announced new funding rounds. In Canada, Entosystem raised new capital for its black soldier fly larvae farming operation.
In no... |
| 30.08.2024 | The Week’s 10 Biggest Funding Rounds: Cribl And Codeium Raise At Huge Valuations | 2 Shares Email Facebook Twitter LinkedIn
Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board.
This is a w... |
| 25.06.2024 | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media | Circio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media
Tue, Jun 25, 2024 07:00 CET Report this content
Circio´s position as a pioneering player in the rapidly... |
| 11.06.2024 | What retailers might do next on health care | figcaption>span]:font-sans" data-chromatic="ignore">
Major retailers are abandoning or scaling back their ambitions to become health care providers — but don't look for them to pull out of the market entirely.
Why it ma... |
| 15.05.2024 | Chinese biotech crackdown would reset U.S. drug development | figcaption>span]:font-sans">
Lawmakers in the House of Representatives on Wednesday are expected to set in motion a massive reordering of how U.S. pharmaceuticals are developed and made, by advancing a contracting ban on five key... |
| 23.04.2024 | Business | Pfizer to shutter Boulder R&D operations | Pharmaceutical giant Pfizer Inc. (NYSE: PFE) will shut down its research and development facility in Boulder in the coming months.
The move, first reported by Endpoints News, will result in an undisclosed number of job cuts. The facility at... |
| 19.02.2024 | Health | Patients see first savings from Biden’s drug price push, as pharma lines up its lawyers | Arthur Allen | KFF Health News (TNS)
Last year alone, David Mitchell paid $16,525 for 12 little bottles of Pomalyst, one of the pricey medications that treat his multiple myeloma, a blood cancer he was diagnosed with in 2010.
The drugs have... |
| 09.02.2024 | Does Moderna’s RSV vaccine lose efficacy faster than others? | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Our podcast this week centers exclusively on a tantalizing subject: Artificial intelligence in biotech. Give it a li... |
| 06.02.2024 | Vertex still knows how to do what it does best | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a close read of the latest blockbuster deal, a look at Novartis’ multibillion-doll... |
| 05.02.2024 | Regeneron is interested in obesity treatments that combat muscle loss | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk about two players that want to join the obesity market with updates to the GLP-1 class: Amgen and Reg... |
| 24.01.2024 | Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey there. So, today we talk about how Eli Lilly’s gene therapy, developed by Akuous, worked in a child born with an... |
| 22.01.2024 | Investigators fault Lilly plant for manufacturing issues | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, lots of regulatory content! We talk about march-in rights and chastening TikTok influencers for their prescri... |
| 19.01.2024 | The Senate health committee looks into its first subpoena in 40 years | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
We’re seeing some rays of hope that this ghastly biotech job market may loosen up a bit. Also, Bernie Sanders wants ... |
| 12.01.2024 | Novartis reportedly decides to pass on Cytokinetics | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya! Did you catch every last important bit of news that emerged from this year’s JPM conference? Join STAT’s Tara ... |
| 09.01.2024 | Anthony Fauci talked Covid in Congress in a nine-hour, closed-door grilling — and that was just day one | You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. What’s the legacy of Xavier Becerra?
... |
| 08.01.2024 | This is the TLDR of JPM Day 1 | In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference, join our newsletter list.
“The lanyards” have landed! A... |
| 07.01.2024 | No pain data yet from Vertex, and sky high deal expectations at JPM 2024 | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Greetings from JPM Week 2024! We’re coming to you live from San Francisco, where the industry’s biggest annual convo... |
| 05.01.2024 | Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy? | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we discuss why a cell therapy stalwart is pivoting, and why a Feng Zhang startup is laying off a quart... |
| 04.01.2024 | Why CG Oncology will be the first test of 2024’s IPO waters | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with an in-depth preview of a certain annual biotech conference, a look at the c... |
| 06.12.2023 | Why Cerevel Therapeutics has risen 50% in three days without changing anything | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with some unrest at well-funded startups, a curious biotech run-up, and long-awaited ne... |
| 04.12.2023 | Novartis is building a new radioligand plant in China | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya. Today, we explore how traditionally underserved sickle cell patients became early recipients of a futuristic g... |
| 01.12.2023 | Johnson & Johnson bets heavy on AI-driven drug discovery | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we talk about Pfizer’s obesity woes, how J&J is leaning heavily into artificial intelligence, chat about h... |
| 28.11.2023 | Today’s biotech news roundup, in under 800 words | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk lots about clinical trial inconsistencies: How Canada’s trial reporting is not up to snuff, and how c... |
| 22.11.2023 | Pharmalittle: European patent agency invalidates a Moderna mRNA patent; pharma ally Eshoo plans to retire | Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalot campus. There won’t be a newsletter this Thursday or Friday because of the Thanksgiving holi... |
| 10.11.2023 | The first vaccine for the increasingly prevalent chikungunya virus is here | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today we have two FDA approvals, preview late-breakers at this weekend’s American Heart Association scientific sessi... |
| 08.11.2023 | BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a close look at an en-vogue idea in oncology, an awkward welcome for a new CEO, an... |
| 14.10.2023 | Inflation Reduction Act’s Drug Pricing Provisions May Lead To Lower Prices In Oncology | The high price of cancer drugs has led to usage of the term "financial toxicity" to describe the ... [+] cost burden on patients. Even where there are multiple competitors in an class of oncology medicines, branded (and some gener... |
| 12.10.2023 | Peter Marks on creating Operation Warp Speed, but for rare diseases | Peter Marks wants drug developers to ask more stupid questions.
It’s part of the top Food and Drug Administration official’s plan to reinvigorate gene therapy, a field that has struggled despite significant technological advances. Some comp... |
| 20.09.2023 | A needle-free anaphylaxis treatment runs into an FDA roadblock | ARS Pharma had high hopes that the FDA on Tuesday would approve its flagship product, a needle-free treatment for adults and children with severe allergic reactions. But instead, the drugmaker was set back with the agency requesting an addi... |
| 07.09.2023 | Pharmalittle: South Africa ‘bullied’ into one-sided Covid vaccine deals; Astellas drops Medicare price-negotiation suit | Good morning, everyone. Jason Mast here filling in for Ed. I learned today from TikTok — burgeoning hub of reliable information that it is — that you can deep-fry coffee beans instead of roasting them, to “soft and almost buttery and rich” ... |
| 01.09.2023 | AstraZeneca bets that gene therapy’s workhorse will still deliver the goods | Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile... |
| 21.08.2023 | Here’s Why Many Americans Are Unable to Afford Their Drugs | America’s pharmaceutical giants are suing this summer to block the federal government’s first effort at drug price regulation.
Last year’s Inflation Reduction Act included what on its face seems a modest proposal: The federal government wou... |
| 08.08.2023 | Impact of new pill to treat postpartum depression will depend on price | The approval of the first-ever pill treating postpartum depression on Friday was hailed as a significant milestone, but it was quickly tempered by questions around how much the drug will cost.
Why it matters: The price of zuranolone will ul... |
| 20.07.2023 | Affini-T Therapeutics shutting down Seattle lab | Affini-T Therapeutics, a cell therapy company spun out of Fred Hutchinson Cancer Research Center that aims to treat solid tumors, is closing its Seattle lab.
Multiple impacted employees posted on LinkedIn about the Seattle office shutting d... |
| 18.07.2023 | ARCH Venture Partners rises to the top of STAT’s 2023 biotech VC rankings | This article is adapted from the 2023 edition of STAT’s annual report, “Ranking biotech’s top venture capital firms.”
ARCH Venture Partners, the long-running investment firm that in recent years has dedicated itself to backing biotechs with... |
| 18.07.2023 | STAT’s 2023 biotech VC rankings show the impact of a volatile market on firms | This article is adapted from the 2023 edition of STAT’s annual report, “Ranking biotech’s top venture capital firms.”
Venture capital firms are notoriously guarded about the kind of financial returns they get back from an individual deal, l... |
| 10.07.2023 | How AI is changing the way scientists engineer drugs, biosensors, enzymes and more | RF Diffusion, a deep learning tool, was prompted to generate a new protein (orange) that binds to the insulin receptor (blue). The tool is now being used by biopharma companies to help design proteins for a variety of uses. Click here for v... |
| 21.06.2023 | Sanofi Goes All-In On AI | Chief Executive Officer of French pharmaceutical giant Sanofi, Paul Hudson, Paris, September 8, ... [+] 2021. (Photo by JOEL SAGET / AFP) (Photo by JOEL SAGET/AFP via Getty Images)AFP via Getty Images |
| 13.06.2023 | A 53-year-old biotech investor is set to be replaced by a 32-year-old exec on Biogen's board. No one disclosed that the new board member is his girlfriend and the mother of his child. | Inside a Biogen laboratory. Biogen said biotech exec Susan Langer was nominated to its board. Biogen
Redeem now
The biotech company Biogen is revamping its board of directors.
A nominee is in a romantic relationship with a departing directo... |
| 11.06.2023 | Following board fight, Francis deSouza resigns as Illumina CEO | Just two weeks after surviving an activist investor’s attempt to oust him from Illumina’s board, company CEO Francis deSouza has resigned his roles at the sequencing behemoth, Illumina said Sunday.
DeSouza stepped down effectively immediate... |
| 07.06.2023 | Mozart Therapeutics lands $25M to develop therapies for autoimmune, inflammatory diseases | Mozart CEO Katie Fanning. (Mozart Photo)
New funding: Seattle biotech company Mozart Therapeutics announced $25 million in new funding Wednesday to further its development of therapies for celiac and other autoimmune conditions.
The therapy... |
| 01.06.2023 | Pharmaceutical Industry Ought To Justify Drug Prices On Value, Not R&D Costs | Lab technician examines microbes through a microscope.getty |
| 13.05.2023 | PBM Reform Legislation May Be One Step Closer To Reality, But It’s Missing Two Key Components | Senator Bill Cassidy, a Republican from Louisiana and ranking member of the Senate Health, ... [+] Education, Labor, and Pensions Committee, speaks beside Senator Bernie Sanders, an Independent from Vermont and chairman of the Senate Health... |
| 10.05.2023 | Three misconceptions about the accelerated drug approval pathway | On Friday, the Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee will meet to discuss the Biologics License Application for Sarepta Therapeutics’ gene therapy delandistrogene moxeparvovec for the treatmen... |
| 08.05.2023 | Rare-disease doctors support expanded newborn genomic screening, survey finds | Plummeting costs of DNA sequencing technologies are injecting urgency into the longstanding debate over whether to dive deeper into the genomes of more infants — even apparently healthy ones.
Experts are divided about how helpful DNA sequen... |
| 02.05.2023 | ICER’s Positive Cost-Effectiveness Assessment Lends Support For New Sickle Cell Disease Gene Therapies | Dr. Steven D. Pearson, the president of the Institute for Clinical and Economic Review (ICER) poses ... [+] for a photograph in Boston on Sept. 10, 2015. (Photo by Jonathan Wiggs/The Boston Globe via Getty Images)Boston Globe via Getty Imag... |
| 25.04.2023 | Lyme disease vaccine could be coming soon | More than two decades after a promising vaccine for Lyme disease was pulled from the market, more tools to protect against the tick-borne illness —including a new shot — are on the horizon.
Why it matters: There's worldwide concern about ho... |
| 21.04.2023 | Tired of ‘dead end’ approach, herpes patients mobilize to demand government action | A medical student spoke emotionally about grappling with a diagnosis his classes told him little about. A young queer man took one test, got a different result on the next, and is now saving up the money needed for the most advanced diagnos... |
| 17.04.2023 | Q&A: What does it mean when a clinical trial is delayed? More than you think | Frank David was just starting an independent research program on cell signaling in cancer and kidney development at a lab in Boston when he realized he’d rather be doing something else.
“I figured out I was more interested in how science tu... |
| 17.04.2023 | VCs 'Complement' European biotech with $79M for retinal AAV gene therapy trial next year | VCs 'Complement' European biotech with $79M for retinal AAV gene therapy trial next year
Endpoints News | By Kyle LaHucik, Associate Editor
Complement Therapeutics raised a €72 million ($79.6 million) Series A to bankroll a Phase Ib of its ... |
| 13.04.2023 | Scientists, going on a bear hunt, find a potential way to treat deadly blood clots | Like many cardiologists, Manuela Thienel spends most days in the chlorinated, temperature-controlled halls of a large hospital. But one week in February 2019, her work brought her to a snowy Swedish forest, where she stood shuddering in a w... |
| 06.04.2023 | Moderna’s CEO Bancel Suggests That Lower Demand For The Covid-19 Vaccine Is A Justification For Quadrupling Of The Price | WASHINGTON, DC - MARCH 22: Senate Health, Education, Labor, and Pensions Committee Chairman Bernie ... [+] Sanders (I-VT) (L) greets Moderna CEO Stephane Bancel before he testifies to the committee in the Hart Senate Office Building on Capi... |
| 05.04.2023 | Are German Drug Pricing Regulations Chasing Some Drug Makers Away, Causing Them To Not Launch Products In The Market? | Bristol Myers Squibb announced it will not be launching its cancer drug, Opdualag, in the German ... [+] market. This follows bluebird bio's exit from the German and European markets, when it failed to reach price agreements for its beta th... |
| 04.04.2023 | Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO | Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO
Endpoints | Kyle LaHucik, Associate Editor
The Wellcome Sanger Institute’s latest oncology spinout will enter the clinic in about 18 to 24 months with a new CEO at the... |
| 28.02.2023 | FDA needs to build in more flexibility for rare disease clinical trials | My toddler, Wheeler, will probably not live to adulthood. Juvenile Batten disease — he has the type known as CLN3 — is stealing his childhood. And then this rare disease will steal my child.
Wheeler is missing the DNA needed to recycle a wa... |
| 16.02.2023 | When Launched, Gene Therapy Roctavian Will Be Administered Mainly In 340B-Eligible Treatment Centers, Where It Will Be Substantially Discounted In Price | Gene editing in vitro.getty |
| 08.02.2023 | Biden’s SOTU Targets Drug Companies, But Misses Opportunity To Challenge Health Insurers And Pharmacy Benefit Managers | In January, drug makers announce increases in list prices of drugs, which can negatively impact ... [+] patients. Health insurers and pharmacy benefit managers also implement changes in drug coverage, to the detriment of patients.getty |
| 27.01.2023 | Top AI startup news of the week: generative AI is blowing up | Check out all the on-demand sessions from the Intelligent Security Summit here.
From ChatGPT “alternatives” to the power of large language models (LLMs) for everything from protein design to note-taking, AI startup news around generative AI... |
| 26.01.2023 | Seattle-area longevity company emerges from three startups, plans to go public via SPAC | Longevity Biomedical CEO Bradford Zakes. (Longevity Photo)
Bradford Zakes recently helped combine the Seattle-area biotech company he led, Cerevast Medical, with two startups to create a new company. Now he’s poised to take Longevity Biomed... |
| 13.01.2023 | Top AI startup news of the week: InstaDeep, DeepL, Pachyderm and more | Check out all the on-demand sessions from the Intelligent Security Summit here.
There were a couple of key artificial intelligence (AI) startup acquisitions this week — in machine learning (ML) decision-making and AI translation — as well a... |
| 02.01.2023 | With FDA Accelerated Approval Of Alzheimer’s Drug Lecanemab Likely January 6th, Discussion Turns To Price And Reimbursement | FILE - This file photo shows a closeup of a human brain affected by Alzheimer's Disease. Lecanemab, ... [+] a beta amyloid-directed monoclonal antibody, has demonstrated modest efficacy - slowing cognitive decline - in a Phase 3 study. (AP ... |
| 21.12.2022 | Tech Moves: Meta exec joins AI startup, Lyell Immunopharma hires new CEO; and more | Claudiu Bulai. (Quantarium Photo)
— Claudiu Bulai is now chief innovation officer at Bellevue, Wash.-based startup Quantarium.
Bulai previously spent five years at Meta, most recently leading engineering for the tech giant’s Reality Labs Re... |
| 19.12.2022 | 33 healthcare and biotech startups investors expect to take off in 2023 | MedArrive; Alma; Abridge; Gilboa Therapeutics; Wheel; OneOncology; Capital Rx; Turquoise Health; Anna Kim/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
We asked top healthcare a... |
| 07.12.2022 | SPAC deal folds for Seattle biotech startup, months after IPO withdrawal | Intrinsic Medicine CEO Alex Martinez. (Intrinsic Photo)
A deal to take Seattle biotech company Intrinsic Medicine public via a SPAC merger has fallen apart.
The SPAC deal, announced in October, would have taken the startup public via a merg... |
| 02.12.2022 | Despite Eye-Popping $3.5 Million Price Tag For Gene Therapy Hemgenix, Budget Impact For Most Payers Will Be Relatively Small | Genetic engineering.getty |
| 02.12.2022 | Pfizer backs $60M infusion into Carrick, teams up on breast cancer treatment | Pfizer backs $60M infusion into Carrick, teams up on breast cancer treatment
Endpoints article | by Katherine Lewin
In a big week for Carrick Therapeutics, the company announced $60 million in funding for its lead breast cancer drug and dev... |
| 29.11.2022 | Seattle startup with fresh approach to Parkinson’s and Alzheimer’s disease raises $96M | Microscopy image of neurons in the mouse brain. (Cajal Neuroscience Image)
Cajal Neuroscience, a Seattle startup taking a unique approach to developing treatments for neurodegenerative diseases like Alzheimer’s and Parkinson’s, revealed mor... |
| 15.11.2022 | FDA’s Push To Reclassify The Opioid Reversal Agent Naloxone As An OTC Product Needs To Show More Urgency | NEW YORK, NY: A package of Narcan (naloxone) nasal spray sits on a counter at a Walgreens pharmacy. ... [+] In 2017, no- or low-cost naloxone - an opioid antagonist - was made available at all pharmacies across New York state. (Photo Illust... |
| 14.11.2022 | Gantenerumab’s Phase 3 Flop Means Lecanemab Emerges As Favorite In Antibody Class Targeting Amyloid Plaque In Alzheimer’s Patients | Doctor viewing brain scans for possible disease or damage.getty |
| 03.11.2022 | We're closer to getting the first new pill to treat UTIs in over 20 years | An experimental antibiotic to treat UTIs showed it worked, leading drugmaker GSK to stop trials early. Darwin Brandis/Getty Images
Redeem now
An experimental antibiotic helped treat urinary tract infections, pharma giant GSK said Thursday.
... |
| 01.11.2022 | Pfizer Hiking Covid Vaccine Prices Against Weaker Demand Speaks Volumes About U.S. Healthcare | Pfizer has announced it will raise the price of its Covid-19 vaccine - which it developed and ... [+] manufactures with BioNTech - fourfold once the federal government is no longer the predominant purchaser (Photo by JOEL SAGET/AFP via Gett... |
| 31.10.2022 | Seattle startup developing therapies based on human milk to go public via SPAC merger | Intrinsic Medicine CEO Alex Martinez. (Intrinsic Medicine Photo)
Seattle startup Intrinsic Medicine plans to go public through a merger with a shell company, Phoenix Biotech Acquisition Corp. The four-year old biotech startup is developing ... |
| 31.10.2022 | Pharmalittle: FDA advisers vote down pediatric brain cancer drug; AbbVie drops out of psoriasis partnership | Good morning, and welcome to a spooky edition of Pharmalittle. It’s Jason Mast here, filling in for Ed. Nothing too scary on the docket — unless you consider broken partnerships and spurned FDA applications scary — but I have dropped a Rees... |
| 20.10.2022 | Drugs Should Be Priced Based On One Factor – Value | For a number of years, the price of drugs has drawn extraordinary attention. Based on the current discourse, one would think that the nation’s healthcare costs were dominated by medicines. In reality, drugs account for less than 15% of all ... |
| 14.10.2022 | Monkeypox vaccine: a case study for real-world data | With health emergencies becoming more common, the world needs more efficient ways to test the safety and effectiveness of drugs, even if they haven’t yet completed the lengthy series of clinical trials the Food and Drug Administration usual... |
| 29.09.2022 | Promising data from large Alzheimer’s study bodes well for this Seattle startup | AltPep CEO and founder Valerie Daggett. (AltPep Photo)
Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai.
The early data ... |
| 25.08.2022 | In the current venture climate, tech for pharma is recession-proof | Among the world’s top 20 pharmaceutical companies, ranked according to their 2021 revenue, 19 generate most of their sales from specialty medicines. Overall, 55 percent of pharmaceutical revenues are driven by specialty drugs. This basic fa... |
| 04.08.2022 | The outsized effect of ‘modest’ price controls on pharmaceutical innovation | Drug price controls in the U.S. Senate are being met with dire warnings that such an approach will stifle innovation, shut off the pipeline of new medicines, and cost lives down the road. Is innovation so fragile that a modest reduction in ... |
| 08.07.2022 | While Conservative Catholics Grab Media Attention On Abortion Issue, Liberal-Leaning Nuns Push Progressive Healthcare Causes Which Most Catholics Support | BOSTON, MA - Sister Simone Campbell, leader of the Nuns on the Bus, spoke during a stop in Boston, ... [+] July 23, 2016. The group of nuns was traveling across the country to draw attention to social inequalities, in healthcare, in particu... |
| 23.06.2022 | Needed: a clearer explanation of why diversity in clinical trials is important | Increasing the diversity of clinical trial participants is all the rage these days. The numbers tell the story: According to Food and Drug Administration data, in 2020 75% of trial participants were white, 11% were Hispanic, 8% were Black, ... |
| 09.06.2022 | David Baker, head of Seattle’s Institute for Protein Design, launches London biotech startup | IPD director David Baker. (IPD Photo)
Prolific biotech co-founder and University of Washington scientist David Baker, head of the UW Institute for Protein Design, has launched a new company.
Charm Therapeutics, based in London, harnesses de... |
| 01.06.2022 | Pfizer’s Not-For-Profit Model For Sales Of Products To Low- And Lower-Middle-Income Countries May Be A Game Changer In Global Health | Pfizer CEO Albert Bourla gestures during a session at the World Economic Forum (WEF) annual meeting ... [+] in Davos on May 25, 2022. - Pfizer said it would sell its patented drugs at a not-for-profit basis to dozens of low- and lower-middl... |
| 27.05.2022 | Coronavirus hasn’t developed resistance to Paxlovid. How long can that last? | When the patient came back 10 days later, coughing repeatedly and complaining of headache, Davey Smith feared the worst.
Smith had prescribed the patient Pfizer’s new antiviral pill, Paxlovid, on the previous visit, after a Covid-19 test ca... |
| 04.05.2022 | FDA Commissioner Califf Says Business Of Health Is Booming In U.S. But Patients’ Outcomes Aren’t Improving | Robert Califf testifies before a Senate Committee on Health, Education, Labor and Pension hearing on ... [+] the nomination to be commissioner of Food and Drug Administration, Tuesday, Dec. 14, 2021. (AP Photo/Manuel Balce Ceneta) ASSOCIATE... |
| 25.04.2022 | Serving as a 'gateway,' Cambridge venture investor closes $300M second fund | Serving as a 'gateway,' Cambridge venture investor closes $300M second fund
Endpoints News article | By Amber Tong, Senior Editor
For a world-renowned and storied academic institution with multiple Nobel laureates and top-notch biomedical r... |
| 09.03.2022 | Altos Labs’ Mega-Startup: Wretched Excess Or The Future Of Biotech…Or Both? | Alta Labs - the biggest biotech startup in history. Photo credit: Getty getty |
| 07.03.2022 | Looking to push checkpoint efficacy, a quiet microbiome upstart bags $67M for clinical work | Looking to push checkpoint efficacy, a quiet microbiome upstart bags $67M for clinical work
Endpoints News article | By Paul Schloesser
Microbiotica has some more funds to work with — $67 million more.
The quiet microbiome therapeutics spin... |
| 18.02.2022 | Justice Department Charges China’s Hytera With Conspiring to Steal Radio Technology | The U.S. Department of Justice unsealed a federal indictment on Feb. 7 charging Chinese telecommunications company Hytera with conspiring with former employees of Motorola Solutions Inc. to steal the American company’s digital mobile radio ... |
| 01.02.2022 | Does Medicare Draft Decision To Restrict Coverage Of Aduhelm Hold Lessons For Future Launches Of Drugs With No Proven Clinical Benefit? | Jay Reinstein, 60, diagnosed with Alzheimer's disease, in Raleigh, North Carolina, U.S., on ... [+] Wednesday, Jan. 12, 2022. The 200,000 Americans who suffer from early-onset Alzheimer's disease received difficult news Tuesday when Medicar... |
| 13.01.2022 | Juno co-founder launches ambitious new startup with Fred Hutch colleagues to treat cancer | From left: Affini-T scientific co-founders and Fred Hutch investigators Philip Greenberg, Aude Chapuis, and Thomas Schmitt. (Fred Hutch Photos)
A new cell therapy company is on the block, propelled by powerhouse scientific co-founders from ... |
| 10.01.2022 | New Year, New Fund, New Opportunities in Bio + Health | 2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and tradit... |
| 03.11.2021 | If Approved, The Novavax Covid-19 Vaccine Could Help Reduce Vaccine Hesitancy In The U.S. | Novavax clinical trial Karen Ducey/Getty Images |
| 26.10.2021 | Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases | Mozart Therapeutics CEO Katie Fanning. (Mozart Photo)
A year and a few months since its founding, Mozart Therapeutics has secured $55 million to develop therapies for celiac disease and other immune-related conditions, the company announced... |
| 26.10.2021 | Decentralized clinical trials platform Medable now valued at $2.1B | In its fourth fundraise in the past two years, decentralized clinical trials startup Medable raised $304 million. The round was co-led by Blackstone Growth, Tiger Global, and returning investor GSR Ventures.
The company has now raised a tot... |
| 14.10.2021 | The cofounder of megabiotech Neumora kept hearing about how difficult it would be to tackle brain disorders. Now she has $500 million to tackle sleep disorders, depression, and anxiety. | United Memorial Medical Center medical staff member Gabriel Cervera Rodriguez examines a patient's MRI images. Go Nakamura/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Red... |
| 27.09.2021 | Digital health news, funding roundup in the prior week; September 27 | UnitedHealthcare makes Apple Fitness available at no cost; Devoted lands $1.2 billion!
More healthtech companies are going public, but are they measuring up? A number of 2021 healthtech companies are trading below their IPO price, with redu... |
| 23.09.2021 | Daily funding roundup - September 23, 2021 | NTWRK raised $50M; Bigeye landed $45M; Meru Health secured $30
Opentrons Labworks: Opentrons Labworks is a Brooklyn, N.Y.-based robotics company focused on helping life scientists automate many of their experiments and processes. Opentrons ... |
| 21.09.2021 | China's biotech industry has quietly surged to a $180 billion behemoth. Here's how it's reshaping biotech as we know it, from M&A to drug pricing | Employees at a pharmaceutical workshop in Haikou, Hainan Province of China. Photo by Yuan Chen/VCG via Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
China's biot... |
| 08.09.2021 | Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway | A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog the small company right into mid-stage testing against cancer.
Diaccurate has in-licensed Merck KGaA’s M2698 — now dubbed DIACC3010 — a “PAM” inhib... |
| 01.09.2021 | 2 top FDA officials resigned over the Biden administration’s booster-shot plan, saying it insisted on the policy before the agency approved it, reports say | President Joe Biden. AP/Manuel Balce Ceneta
The FDA announced the resignations of Marion Gruber and Philip Krause on Tuesday.
The pair lead the FDA office in charge of approving vaccines.
Politico and Endpoints reported that the pair left i... |
